Unibest

Pharmaceutical intermediates

Sofosbuvir Intermediates

2 pharmaceutical intermediates for Sofosbuvir. Indication: Hepatitis C, Chronic; Hepatitis C.

Submit a ProjectAll intermediates

About Sofosbuvir

Originator
Gilead Sciences Inc
Indication
Hepatitis C, Chronic; Hepatitis C
Approved Date
08/28/2019
DS/DP
03/21/2028

Available intermediates

2 intermediates currently listed for Sofosbuvir. Request specifications, documentation or a quotation for any item below.

Sofosbuvir intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
2'-Deoxy-2'-fluoro-2'- Methyl-N-(phenylcarbonyl) cytidine817204-32-3//
2'-deoxy-2'-fluoro-2'-C-methyluridine863329-66-2//

Other programs under S

SaracatinibSarecycline HydrochlorideSarolanerSaxagliptinSeladelparSeltorexantSemaglutideSitafloxacin hydrate

Building toward Sofosbuvir?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

Submit a Project Talk to the team

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here

Contact Us →